Basic Information
-
Targeting Strategy
-
Gene targeting strategy for B-hPD-1/hCD40 mice. The exon 2 of mouse Pd-1 gene that encodes the extracellular domain was replaced by human PD-1 exon 2 in B-hPD-1/hCD40 mice. The exons 2-7 of mouse Cd40 gene that encode the extracellular domain were replaced by human CD40 exons 2-7 in B-hPD-1/hCD40 mice. The B-hPD-1/hCD40 two knock-in model, was developed by breeding the B-hPD-1 mice and the B-hCD40 mice, has a functional mouse immune system.
-
Details
-
Phenotype
Protein Expression Analysis
Combination therapy of PD-1 mAb (keytruda) and CD40 mAb
Antitumor activity of anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda in B-hPD-1/hCD40 mice. (A) Anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibodies keytruda inhibited MC38-hPD-L1 tumor growth in B-hPD-1/hCD40 mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hCD40 mice (female, 6 week-old, n=8). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hCD40 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hCD40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hCD40 antibodies and hPD-1 antibodies .Values are expressed as mean ± SEM.
Combination therapy of PD-1 mAb (keytruda) and CD40 mAb
Antitumor activity of anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda in B-hPD-1/hCD40 mice. (A) Anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibodies keytruda inhibited MC38 tumor growth in B-hPD-1/hCD40 mice. Murine colon cancer MC38 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hCD40 mice (female, 4 week-old, n=8). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hCD40 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hCD40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hCD40 antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.
Combination therapy of PD-1 mAb (keytruda) and CD40 mAb
Antitumor activity of anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda in B-hPD-1/hCD40 mice. (A) Anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibodies keytruda inhibited B16F10-hPD-L1 tumor growth in B-hPD-1/hCD40 mice. Murine colon cancer B16F10-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hCD40 mice (female, 8 week-old, n=8). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hCD40 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hCD40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hCD40 antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.
-
References
-
- Nat Commun.2017 Feb 6; 8 :14369. doi: 10.1038/ncomms14369.
- EMBO J.1992 Nov;11(11):3887-95.
- Sci. Transl. Med. 10, eaan4488 (2018) doi: 10.1126/scitranslmed. aan4488